---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-04-22T22:26:32.226988'
end_time: '2026-04-22T22:38:13.319812'
duration_seconds: 701.09
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Blau Syndrome
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 32
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Blau Syndrome
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Blau Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (MAXO terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Blau Syndrome
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Blau Syndrome** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (MAXO terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


# Blau Syndrome (Mendelian) — Comprehensive Disease Characteristics Report

**Target disease:** Blau syndrome (familial juvenile systemic granulomatosis; sporadic counterpart often termed early-onset sarcoidosis). (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2)

**Evidence base note:** The synthesis below is derived from aggregated disease-level publications (case series/cohorts, mechanistic studies, and ClinicalTrials.gov records), not from EHR-only sources. (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2, NCT06660329 chunk 1)

---

## 1. Disease Information

### 1.1 Overview (current understanding)
Blau syndrome is a rare, typically pediatric-onset, systemic autoinflammatory granulomatous disorder classically defined by the triad of **granulomatous dermatitis**, **symmetric arthritis/tenosynovitis**, and **recurrent uveitis**. (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2)

### 1.2 Key identifiers (best available from retrieved sources)
* **OMIM disease:** *Blau syndrome* **#186580**. (brichova2024blausyndromechallenging pages 1-2)
* **Gene:** **NOD2** (also referenced historically as **CARD15**). (shi2025longtermprognosisof pages 1-2, zhang2026clinicalfeaturestreatment pages 9-10)
* **MONDO ID / Orphanet / ICD / MeSH:** Not available in the retrieved evidence set; should be added from external disease ontologies during downstream curation.

### 1.3 Synonyms / alternative names
* Blau syndrome (BS). (brichova2024blausyndromechallenging pages 1-2)
* Juvenile systemic granulomatosis (commonly used in reviews/clinical discussion; not explicitly enumerated in the extracted text set).
* Early-onset sarcoidosis (EOS) is commonly used for sporadic/de novo presentations and is described as the “sporadic counterpart” in clinical genetics contexts. (shi2025longtermprognosisof pages 1-2, brichova2024blausyndromechallenging pages 11-13)

---

## 2. Etiology

### 2.1 Disease causal factors
**Primary cause:** heterozygous variants in **NOD2**, producing a dominantly inherited autoinflammatory granulomatous disorder. (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2)

**Key concept (mechanistic genotype class):** Blau-associated NOD2 variants behave as **gain-of-function** with constitutive pro-inflammatory signaling (see §6). (matsuda2022potentialbenefitsof pages 1-2, ueki2023tofacitinibasuppressor pages 1-2)

### 2.2 Risk factors
* **Genetic risk factor (causal):** pathogenic **NOD2** variants—especially in the **exon 4 hotspot** (see §4). (brichova2024blausyndromechallenging pages 2-4)
* **Environmental risk factors:** No consistent environmental exposures are established as causal in the retrieved sources; however, **immune priming signals** (e.g., IFN-γ–driven pathways) are mechanistically implicated as triggers/accelerants (see §6). (ueki2023tofacitinibasuppressor pages 1-2)

### 2.3 Protective factors
No protective genetic or environmental factors were identified in the retrieved sources.

### 2.4 Gene–environment interactions
Direct gene–environment interaction evidence is limited. Mechanistic work supports a model in which inflammatory cytokine milieus (notably **IFN-γ**) upregulate NOD2 expression and exacerbate inflammatory outputs specifically in mutant-NOD2 cells. (ueki2023tofacitinibasuppressor pages 1-2, ueki2023tofacitinibasuppressor pages 3-5)

---

## 3. Phenotypes (clinical features)

### 3.1 Core phenotypes and frequencies (recent cohort statistics)
The largest quantitative phenotype set in the retrieved evidence is a **47-patient pediatric cohort** from a Chinese tertiary center (publication date **May 2025**). Key baseline frequencies:
* **Arthritis:** **93.6%** (44/47). (shi2025longtermprognosisof pages 1-2)
* **Rash/dermatitis:** **72.3%** (34/47). (shi2025longtermprognosisof pages 1-2)
* **Uveitis:** **31.9%**. (shi2025longtermprognosisof pages 1-2)
* **Fever:** **34%**. (shi2025longtermprognosisof pages 1-2)
* **Classic triad present:** ~**30%**. (shi2025longtermprognosisof pages 1-2)
* **Vasculitis:** **27.7%**; **interstitial lung disease:** **17.0%**; **hypertension:** **8.5%**; **cardiac enlargement:** **6.4%**; **deafness:** **6.4%**; **microscopic hematuria:** **4.3%**. (shi2025longtermprognosisof pages 1-2)

In this cohort, arthritis commonly involved **ankles (90.9%)**, **wrists (72.3%)**, and **knees (70.2%)** among those with arthritis. (shi2025longtermprognosisof pages 2-4)

A separate **13-patient Chinese cohort** (10-year experience; publication date **Feb 2026**) reported: arthritis 100% (13/13), ocular involvement 92.3% (12/13), joint deformity 76.9% (10/13), and full triad 69.2% (9/13). (zhang2026clinicalfeaturestreatment pages 1-2)

### 3.2 Age of onset and course
Blau syndrome is typically **early childhood-onset**. In the 47-patient cohort, median onset was **13.64 months** (range 1–51 months). (shi2025longtermprognosisof pages 1-2)

Progression can be organ-specific: skin manifestations may resolve in some individuals, while joint and eye disease can be progressive and lead to severe complications such as joint contracture and blindness (review-level statement). (matsuda2022potentialbenefitsof pages 1-2)

### 3.3 Quality-of-life impact
Visual morbidity is a major driver of disability: in a 2024 clinical genetics review/case series, >25% of patients were reported to suffer moderate-to-severe visual loss, although 10–20% may lack ocular involvement (review-level summary). (brichova2024blausyndromechallenging pages 1-2)

### 3.4 Suggested HPO terms (non-exhaustive)
(Provided as ontology suggestions for knowledge-base annotation)
* Arthritis: **HP:0001369**
* Tenosynovitis / synovitis: **HP:0100769** (synovitis)
* Uveitis: **HP:0000554**
* Panuveitis: **HP:0012113**
* Granulomatous dermatitis: **HP:0100710** (dermatitis) + modifier “granulomatous” (not always explicitly represented)
* Rash: **HP:0000988**
* Fever: **HP:0001945**
* Interstitial lung disease: **HP:0006530**
* Vasculitis: **HP:0002633**
* Camptodactyly (commonly described in Blau): **HP:0012385** (reported as ~60% in a recent review/case-series summary). (brichova2024blausyndromechallenging pages 1-2)
* Hypertension: **HP:0000822**
* Hearing impairment: **HP:0000365**
* Hematuria: **HP:0000790**

---

## 4. Genetic / Molecular Information

### 4.1 Causal gene
**NOD2** is the causal gene for Blau syndrome (dominant autoinflammatory granulomatous disease). (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2)

### 4.2 Pathogenic variants and hotspots
A key practical point for molecular diagnosis is the **NOD2 exon 4 hotspot**, where the most recurrent Blau mutations occur. (brichova2024blausyndromechallenging pages 2-4)

Frequently cited pathogenic variants include:
* **NOD2 c.1001G>A p.(Arg334Gln) [R334Q]** (brichova2024blausyndromechallenging pages 1-2)
* **NOD2 c.1000C>T p.(Arg334Trp) [R334W]** (brichova2024blausyndromechallenging pages 1-2)

In the 47-patient Chinese cohort, **12 distinct NOD2 variants** were identified; the authors report genotype–phenotype associations including that **R334Q** was associated with arthritis, rash, uveitis and fever, whereas **R334W** was associated with arthritis, rash and fever. (shi2025longtermprognosisof pages 1-2)

A 2024 case series emphasized that the **pathogenicity interpretation of novel or VUS findings** can be challenging, highlighting examples such as a novel NOD2 variant absent in gnomAD and an additional NLRC4 truncating VUS that likely did not explain the phenotype. (brichova2024blausyndromechallenging pages 6-8)

### 4.3 Variant classification and interpretation challenges
A 2024 diagnostic genetics case series used ACMG/AMP frameworks and highlighted difficulties in assigning causality when **variants of uncertain significance (VUS)** or **dual diagnoses** confound classic clinical interpretation. (brichova2024blausyndromechallenging pages 2-4, brichova2024blausyndromechallenging pages 8-10)

### 4.4 Functional consequences (current understanding)
Functional studies and reviews in the retrieved evidence emphasize that Blau-associated NOD2 mutations can cause **ligand-independent/constitutive NF-κB transcriptional activity**, consistent with gain-of-function inflammatory signaling. (matsuda2022potentialbenefitsof pages 1-2, ueki2023tofacitinibasuppressor pages 1-2)

---

## 5. Environmental Information

No reproducible external environmental/toxic/lifestyle risk factors were identified in the retrieved evidence set. The disease biology is primarily driven by Mendelian NOD2 variation, though immune stimuli (e.g., IFN-γ signaling) likely influence disease activity (see §6). (ueki2023tofacitinibasuppressor pages 1-2)

---

## 6. Mechanism / Pathophysiology

### 6.1 Upstream-to-downstream causal chain (evidence-supported)
1. **Triggering context / priming:** IFN-γ signaling increases NOD2 expression in myeloid cells; this appears to be an important “priming” step in cellular models of Blau syndrome. (matsuda2022potentialbenefitsof pages 4-6, ueki2023tofacitinibasuppressor pages 1-2)
2. **Mutant receptor signaling:** Blau-associated mutant NOD2 shows constitutive inflammatory signaling.
   * Abstract-level quote: Blau-associated NOD2 mutants “spontaneously promoted NF-kB transcription ... even without the addition of MDP” (i.e., ligand-independent). (matsuda2022potentialbenefitsof pages 1-2)
3. **Cytokine amplification and granulomatous inflammation:** In ex vivo/iPSC-derived models, inflammatory cytokine dysregulation in macrophages requires IFN-γ stimulation and can be corrected by anti-TNF therapy, implying a TNF-dependent amplification layer relevant to granulomatous pathology. (matsuda2022potentialbenefitsof pages 1-2)

### 6.2 Key molecular pathways (annotatable)
* **NF-κB activation** downstream of NOD2 and associated cytokine programs. (matsuda2022potentialbenefitsof pages 1-2, ueki2023tofacitinibasuppressor pages 1-2)
* **IFN-γ → JAK/STAT signaling** as an upstream regulator of NOD2 expression and inflammatory mediator induction in mutant cells. (ueki2023tofacitinibasuppressor pages 1-2, ueki2023tofacitinibasuppressor pages 3-5)
* **TNF-mediated inflammatory signaling** as a therapeutically actionable node supported by ex vivo correction and cohort-level clinical experience. (matsuda2022potentialbenefitsof pages 1-2, shi2025longtermprognosisof pages 1-2)

### 6.3 Immune cells and tissues (cell ontology suggestions)
Evidence in the retrieved set supports a central role for **macrophage-lineage myeloid cells** in mechanistic assays (patient iPSC-derived monocytic/macrophage-like cells) and granulomatous inflammation. (ueki2023tofacitinibasuppressor pages 3-5, matsuda2022potentialbenefitsof pages 1-2)

Suggested CL terms (ontology suggestions):
* Macrophage: **CL:0000235**
* Monocyte: **CL:0000576**
* Neutrophil: **CL:0000775** (supported indirectly by tear proteomics neutrophil granule signature in severe ocular disease). (galozzi2024proteomicprofilingof pages 1-2, galozzi2024proteomicprofilingof pages 4-6)

### 6.4 GO biological process suggestions (ontology suggestions)
* NF-κB signaling: **GO:0043122** (regulation of I-kappaB kinase/NF-kappaB signaling)
* Response to interferon-gamma: **GO:0034341**
* Cytokine-mediated signaling pathway: **GO:0019221**
* Granuloma formation: can be proxied by terms related to “inflammatory response” (**GO:0006954**) and macrophage activation.

### 6.5 Recent mechanistic developments (2023–2024 priority)
**JAK inhibition as upstream control of NOD2 expression:** A 2023 mechanistic study tested tofacitinib in mutant-NOD2 contexts and concluded that it suppresses IFN-γ-induced NOD2 expression and downstream cytokines rather than directly shutting off mutant NOD2’s basal NF-κB activity.
* Abstract quote: “Tofacitinib did not suppress the increased spontaneous transcriptional activity of NF-kB by mutant NOD2.” (ueki2023tofacitinibasuppressor pages 1-2)
* Abstract quote: IFN-γ induction “led to the production of inflammatory cytokines by an autoinflammatory mechanism only in cells with mutant NOD2.” (ueki2023tofacitinibasuppressor pages 1-2)

---

## 7. Anatomical Structures Affected

### 7.1 Organ systems (evidence-supported)
* **Joints / synovium / tendon sheaths:** high-frequency arthritis/tenosynovitis. (shi2025longtermprognosisof pages 1-2)
* **Eye / uvea / retina-choroid:** uveitis and panuveitis; a major morbidity driver. (brichova2024blausyndromechallenging pages 4-6, shi2025longtermprognosisof pages 1-2)
* **Skin:** granulomatous dermatitis/rash. (shi2025longtermprognosisof pages 1-2)
* **Lung:** interstitial lung disease in a subset (17% in one cohort). (shi2025longtermprognosisof pages 1-2)
* **Vascular system:** vasculitis in a subset (27.7% in one cohort). (shi2025longtermprognosisof pages 1-2)
* **Kidney/urinary:** microscopic hematuria in a subset; renal involvement is discussed in multisystem descriptions. (shi2025longtermprognosisof pages 1-2, brichova2024blausyndromechallenging pages 4-6)

### 7.2 UBERON term suggestions (ontology suggestions)
* Synovial joint: **UBERON:0000169**
* Uvea: **UBERON:0001769**
* Skin: **UBERON:0002097**
* Lung: **UBERON:0002048**
* Kidney: **UBERON:0002113**

---

## 8. Temporal Development

### 8.1 Onset
Clinical manifestations often begin **before age 4** (review-level) and can begin in infancy (median 13.64 months in the pediatric cohort). (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2)

### 8.2 Progression patterns
The disease course is typically chronic with progressive risk for joint deformity and ocular complications; a 13-patient cohort reported joint deformity in 76.9%. (zhang2026clinicalfeaturestreatment pages 1-2)

---

## 9. Inheritance and Population

### 9.1 Inheritance
Autosomal dominant inheritance is typical; de novo/sporadic cases occur.
* In the 47-patient pediatric cohort: familial 17% and sporadic 83%. (shi2025longtermprognosisof pages 2-4)

### 9.2 Epidemiology
Population prevalence/incidence estimates were not available in the retrieved evidence set (common limitation for ultra-rare Mendelian autoinflammatory diseases).

### 9.3 Sex ratio and demographics
In the 47-patient cohort, 26/47 were male and 21/47 female. (shi2025longtermprognosisof pages 1-2)

---

## 10. Diagnostics

### 10.1 Clinical criteria and confirmatory testing
Diagnosis is typically based on:
1. **Clinical triad** (dermatitis + arthritis/tenosynovitis + uveitis), and/or
2. **Histopathology** demonstrating **non-caseating granulomas**, and
3. **Genetic confirmation** of a pathogenic **NOD2** variant. (shi2025longtermprognosisof pages 1-2, brichova2024blausyndromechallenging pages 2-4)

### 10.2 Genetic testing approach (real-world practice)
A practical approach used in a 2024 case series was to perform **targeted Sanger sequencing of the NOD2 exon 4 hotspot** in probands, supplemented by broader autoinflammatory gene panels and exome sequencing in select cases (e.g., atypical presentations, VUS, or phenocopies). (brichova2024blausyndromechallenging pages 2-4)

### 10.3 Diagnostic delays and misdiagnosis
Diagnostic delay is substantial:
* Pediatric cohort: median diagnosis ~54.9 months with ~41.2 months delay. (shi2025longtermprognosisof pages 2-4)
* 2024 case series: delays of 2–23 years (mean 9), with misdiagnosis as atopic dermatitis or juvenile idiopathic arthritis noted. (brichova2024blausyndromechallenging pages 11-13)

### 10.4 Differential diagnosis (evidence-based examples)
The 2024 diagnostic genetics report highlights challenges distinguishing Blau syndrome from other granulomatous or inflammatory conditions and emphasizes that biopsy and careful genetic interpretation may be required in atypical cases (e.g., neurological features mimicking neurosarcoidosis). (brichova2024blausyndromechallenging pages 2-4, brichova2024blausyndromechallenging pages 1-2)

### 10.5 Biomarkers and omics-based diagnostics (2024 development)
**Tear proteomics (Aug 2024, IJMS)** provides a candidate biomarker direction for ocular involvement.
* 387 tear proteins identified; differential expression defined using fold-change thresholds and multiple testing correction. (galozzi2024proteomicprofilingof pages 2-4)
* Candidate biomarkers upregulated in Blau vs controls include **A2M** and **IGHG4** (e.g., IGHG4 FC ~10; A2M FC ~5–6.7 depending on comparison). (galozzi2024proteomicprofilingof pages 4-6)
* In severe ocular disease, neutrophil granule proteins were markedly elevated compared with milder cases (e.g., MPO FC 16.50; AZU1 FC 24.84; DEFA3 FC 9.93). (galozzi2024proteomicprofilingof pages 4-6)

---

## 11. Outcome / Prognosis

### 11.1 Disease control rates under current treatment (cohort statistic)
In the 47-patient cohort, 72.3% achieved disease control at latest follow-up; TNF-α inhibitor-treated patients had higher remission rates (association reported in the cohort). (shi2025longtermprognosisof pages 1-2)

### 11.2 Major complications
Ocular involvement is a major morbidity driver with risk of vision loss (review-level). (brichova2024blausyndromechallenging pages 1-2)

Mortality and life expectancy statistics were not available in the retrieved evidence set.

---

## 12. Treatment

### 12.1 Current real-world management (cohort-based)
From the 47-patient pediatric cohort (May 2025):
* **Prednisolone + methotrexate:** used in **95.7%** (45/47). (shi2025longtermprognosisof pages 1-2)
* **TNF-α inhibitors:** used in **42.6%** (20/47). (shi2025longtermprognosisof pages 1-2)
* **Disease control at follow-up:** **72.3%** (34/47), with higher remission in TNFi-treated patients. (shi2025longtermprognosisof pages 1-2)

A 13-patient cohort described high TNFi uptake (12/13) with initial complete remissions on infliximab/etanercept/adalimumab in subsets and frequent relapse/secondary loss of efficacy over time (46.2% relapse/secondary loss reported). (zhang2026clinicalfeaturestreatment pages 1-2)

### 12.2 Mechanism-based therapeutic rationale (authoritative review)
A mechanistic review concluded that although multiple therapies (IL-1, IL-6, JAK inhibitors) have been reported, **anti-TNF therapy plays a central role**. (matsuda2022potentialbenefitsof pages 1-2)

Ex vivo mechanistic support:
* “abnormal cytokine expression in macrophages … requires IFNg stimulation,” and “anti-TNF treatment corrects the abnormalities … even in the presence of IFNg.” (matsuda2022potentialbenefitsof pages 1-2)

### 12.3 Recent developments (2023–2024 priority)
**JAK inhibitors / tofacitinib mechanistic study (Jun 2023):** supports upstream blockade of IFN-γ-induced NOD2 expression and cytokines.
* Quote: “Tofacitinib did not suppress the increased spontaneous transcriptional activity of NF-kB by mutant NOD2.” (ueki2023tofacitinibasuppressor pages 1-2)
* Quote: Tofacitinib suppressed IFN-γ-induced NOD2 induction “thereby inhibiting the production of pro-inflammatory cytokines.” (ueki2023tofacitinibasuppressor pages 1-2)

**Biomarker development (Aug 2024):** tear proteomics identifies candidate ocular biomarkers and highlights neutrophil granule proteins in severe disease. (galozzi2024proteomicprofilingof pages 4-6)

### 12.4 Experimental/clinical trials (ClinicalTrials.gov)
* **NCT06660329 (posted 2024; start 2024-10-01):** “Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome,” Phase 4, open-label single-group, estimated n=30 pediatric participants; primary outcome is remission/low disease activity at 6 months; includes longitudinal inflammatory markers/cytokines including TNFα and IFNγ. URL: https://clinicaltrials.gov/study/NCT06660329 (NCT06660329 chunk 1)
* **NCT06688838 (posted 2024-11-14):** retrospective cohort comparing glucocorticoid+DMARDs vs +TNFi vs +tofacitinib, estimated n=24. URL: https://clinicaltrials.gov/study/NCT06688838 (NCT06688838 chunk 1)

### 12.5 MAXO term suggestions (ontology suggestions)
* Systemic glucocorticoid therapy
* Methotrexate therapy
* Tumor necrosis factor inhibitor therapy
* Janus kinase inhibitor therapy
* Interleukin-1 inhibitor therapy
* Interleukin-6 receptor inhibitor therapy
* Ophthalmologic monitoring and uveitis-directed therapy

---

## 13. Prevention

Because Blau syndrome is a Mendelian dominant disorder, prevention focuses on **genetic counseling** and **cascade testing** in families with known pathogenic NOD2 variants; no primary prevention strategies are established in the retrieved evidence set. (brichova2024blausyndromechallenging pages 2-4)

---

## 14. Other Species / Natural Disease

No naturally occurring non-human Blau syndrome analogs were identified in the retrieved evidence set.

---

## 15. Model Organisms / Experimental Models

### 15.1 Human cell models (strongest evidence in retrieved set)
A 2023 mechanistic study used **patient-derived induced pluripotent stem cell (iPSC)–derived monocytic/myeloid cells** to test IFN-γ induction of NOD2 and cytokine production and to examine tofacitinib effects. (ueki2023tofacitinibasuppressor pages 3-5, ueki2023tofacitinibasuppressor pages 1-2)

### 15.2 Suggested model utility
Such iPSC-derived myeloid models are useful for:
* probing **IFN-γ–priming** of mutant-NOD2 inflammatory outputs;
* testing **JAK inhibition** as a strategy to block cytokine-driven induction of NOD2 expression. (ueki2023tofacitinibasuppressor pages 3-5, ueki2023tofacitinibasuppressor pages 1-2)

---

## Key visual evidence
The 2024 Genes case series includes a **family-variant figure** and a **clinical feature table** useful for knowledge-base validation and phenotype capture. (brichova2024blausyndromechallenging media 5971238a, brichova2024blausyndromechallenging media 2378c737)

---

## Structured summary table

| Domain | Key points (with quantitative data where available) | Best recent source (first author year) | URL |
|---|---|---|---|
| Definition / triad | Rare pediatric autoinflammatory granulomatous disease defined by the classic triad of granulomatous dermatitis, symmetric arthritis/tenosynovitis, and recurrent uveitis; early-onset sarcoidosis is generally considered the sporadic counterpart (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2) | Brichova 2024 | https://doi.org/10.3390/genes15060799 |
| Inheritance | Usually autosomal dominant due to heterozygous gain-of-function NOD2 variants; Chinese pediatric cohort: 17% familial and 83% sporadic/de novo among 47 cases (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 2-4) | Brichova 2024 | https://doi.org/10.3390/genes15060799 |
| Onset age | Clinical manifestations typically begin before age 3–4 years; Chinese cohort median onset 13.64 months (range 1–51 months) (brichova2024blausyndromechallenging pages 1-2, shi2025longtermprognosisof pages 1-2) | Shi 2025 | https://doi.org/10.1186/s12887-025-05584-x |
| Key phenotype frequencies (Shi cohort, n=47) | Arthritis 93.6% (44/47); rash/dermatitis 72.3% (34/47); fever 34%; uveitis 31.9%; full triad in ~30%; vasculitis 27.7%; interstitial lung disease 17.0%; hypertension 8.5%; cardiac enlargement 6.4%; deafness 6.4%; microscopic hematuria 4.3% (shi2025longtermprognosisof pages 1-2, shi2025longtermprognosisof pages 2-4) | Shi 2025 | https://doi.org/10.1186/s12887-025-05584-x |
| Diagnostic delay | Chinese cohort: median diagnosis age 54.9 months with median diagnostic delay ~41.2 months; 2024 Czech series reports delays of 2–23 years (mean 9 years), underscoring frequent under-recognition/misdiagnosis (shi2025longtermprognosisof pages 2-4, brichova2024blausyndromechallenging pages 11-13) | Shi 2025 | https://doi.org/10.1186/s12887-025-05584-x |
| Causal gene / hotspot variants | Causal gene: NOD2 (CARD15). Exon 4 is a mutational hotspot; p.Arg334Gln (R334Q) and p.Arg334Trp (R334W) are the best-known recurrent pathogenic variants. In the Chinese cohort, R334Q correlated with arthritis, rash, uveitis, fever; R334W with arthritis, rash, fever (brichova2024blausyndromechallenging pages 2-4, shi2025longtermprognosisof pages 1-2) | Brichova 2024 | https://doi.org/10.3390/genes15060799 |
| Mechanism | Core mechanism: Blau-associated NOD2 mutants show constitutive/ligand-independent NF-κB activation; IFN-γ acts as a priming signal by upregulating NOD2 in patient macrophage models; anti-TNF can correct IFN-γ-associated cytokine abnormalities ex vivo, supporting TNF dependence in downstream inflammation/granuloma biology (matsuda2022potentialbenefitsof pages 1-2, matsuda2022potentialbenefitsof pages 4-6, ueki2023tofacitinibasuppressor pages 1-2) | Ueki 2023 | https://doi.org/10.3389/fimmu.2023.1211240 |
| Treatment outcomes | In the 47-patient Chinese cohort, 95.7% (45/47) received prednisolone + methotrexate and 42.6% (20/47) received TNF inhibitors; 72.3% (34/47) achieved disease control at last follow-up, with higher remission rates in TNFi-treated patients (shi2025longtermprognosisof pages 1-2) | Shi 2025 | https://doi.org/10.1186/s12887-025-05584-x |
| JAK inhibitor rationale | Tofacitinib did not suppress mutant-NOD2-driven basal NF-κB directly, but it suppressed IFN-γ-induced NOD2 expression and reduced downstream pro-inflammatory cytokine production in Blau iPSC-derived myeloid cells; this provides an upstream mechanistic rationale for JAK inhibition in refractory disease (ueki2023tofacitinibasuppressor pages 1-2, ueki2023tofacitinibasuppressor pages 3-5) | Ueki 2023 | https://doi.org/10.3389/fimmu.2023.1211240 |
| Tear proteomics / biomarkers | 2024 tear proteomics identified 387 proteins. In affected p.E383K carriers, A2M and IGHG4 were highlighted as candidate biomarkers; quantitative examples include A2M FC 5.03 (vs unaffected family) and 6.75 (vs controls), IGHG4 FC ~10.17 and ~10.28, haptoglobin FC 5.71, SERPINA3 FC 5.71. In the most severe ocular case, neutrophil-granule proteins were elevated, including MPO FC 16.50, AZU1 FC 24.84, DEFA3 FC 9.93 (galozzi2024proteomicprofilingof pages 1-2, galozzi2024proteomicprofilingof pages 2-4, galozzi2024proteomicprofilingof pages 4-6, galozzi2024proteomicprofilingof pages 12-14) | Galozzi 2024 | https://doi.org/10.3390/ijms25158387 |


*Table: This table condenses the most actionable facts for Blau syndrome across definition, genetics, mechanism, phenotype frequencies, and treatment response. It emphasizes recent cohort and mechanistic studies that are useful for rapid knowledge-base population.*

---

## Limitations of this report (evidence availability)
* **Prevalence/incidence** estimates and **mortality/life expectancy** were not available in the retrieved documents.
* **MONDO/Orphanet/ICD/MeSH identifiers** were not retrievable from the current evidence set and should be added via dedicated ontology lookups.
* **PMIDs** were not provided in the extracted tool context for these papers; DOI and publication dates are provided where available in-source.


References

1. (brichova2024blausyndromechallenging pages 1-2): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

2. (shi2025longtermprognosisof pages 1-2): Xinwei Shi, Jianghong Deng, Junmei Zhang, Xiaozhen Zhao, Yinan Zhao, Li Li, Fengqiao Gao, Weiying Kuang, Jiang Wang, Xiaohua Tan, Chao Li, Shipeng Li, and Caifeng Li. Long-term prognosis of 47 pediatric patients with blau syndrome in china. BMC Pediatrics, May 2025. URL: https://doi.org/10.1186/s12887-025-05584-x, doi:10.1186/s12887-025-05584-x. This article has 2 citations and is from a peer-reviewed journal.

3. (NCT06660329 chunk 1): Hongmei Song. Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome. Peking Union Medical College Hospital. 2024. ClinicalTrials.gov Identifier: NCT06660329

4. (zhang2026clinicalfeaturestreatment pages 9-10): Jingyuan Zhang and Min Shen. Clinical features, treatment strategies, and long-term outcomes of blau syndrome: a 10-year experience from a chinese cohort. Advances in Rheumatology, Feb 2026. URL: https://doi.org/10.1186/s42358-026-00528-0, doi:10.1186/s42358-026-00528-0. This article has 0 citations.

5. (brichova2024blausyndromechallenging pages 11-13): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

6. (matsuda2022potentialbenefitsof pages 1-2): Tomoko Matsuda, Naotomo Kambe, Riko Takimoto-Ito, Yoko Ueki, Satoshi Nakamizo, Megumu K. Saito, Syuji Takei, and Nobuo Kanazawa. Potential benefits of tnf targeting therapy in blau syndrome, a nod2-associated systemic autoinflammatory granulomatosis. Frontiers in Immunology, May 2022. URL: https://doi.org/10.3389/fimmu.2022.895765, doi:10.3389/fimmu.2022.895765. This article has 27 citations and is from a peer-reviewed journal.

7. (ueki2023tofacitinibasuppressor pages 1-2): Yoko Ueki, Riko Takimoto-Ito, Megumu K. Saito, Hideaki Tanizaki, and Naotomo Kambe. Tofacitinib, a suppressor of nod2 expression, is a potential treatment for blau syndrome. Frontiers in Immunology, Jun 2023. URL: https://doi.org/10.3389/fimmu.2023.1211240, doi:10.3389/fimmu.2023.1211240. This article has 16 citations and is from a peer-reviewed journal.

8. (brichova2024blausyndromechallenging pages 2-4): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

9. (ueki2023tofacitinibasuppressor pages 3-5): Yoko Ueki, Riko Takimoto-Ito, Megumu K. Saito, Hideaki Tanizaki, and Naotomo Kambe. Tofacitinib, a suppressor of nod2 expression, is a potential treatment for blau syndrome. Frontiers in Immunology, Jun 2023. URL: https://doi.org/10.3389/fimmu.2023.1211240, doi:10.3389/fimmu.2023.1211240. This article has 16 citations and is from a peer-reviewed journal.

10. (shi2025longtermprognosisof pages 2-4): Xinwei Shi, Jianghong Deng, Junmei Zhang, Xiaozhen Zhao, Yinan Zhao, Li Li, Fengqiao Gao, Weiying Kuang, Jiang Wang, Xiaohua Tan, Chao Li, Shipeng Li, and Caifeng Li. Long-term prognosis of 47 pediatric patients with blau syndrome in china. BMC Pediatrics, May 2025. URL: https://doi.org/10.1186/s12887-025-05584-x, doi:10.1186/s12887-025-05584-x. This article has 2 citations and is from a peer-reviewed journal.

11. (zhang2026clinicalfeaturestreatment pages 1-2): Jingyuan Zhang and Min Shen. Clinical features, treatment strategies, and long-term outcomes of blau syndrome: a 10-year experience from a chinese cohort. Advances in Rheumatology, Feb 2026. URL: https://doi.org/10.1186/s42358-026-00528-0, doi:10.1186/s42358-026-00528-0. This article has 0 citations.

12. (brichova2024blausyndromechallenging pages 6-8): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

13. (brichova2024blausyndromechallenging pages 8-10): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

14. (matsuda2022potentialbenefitsof pages 4-6): Tomoko Matsuda, Naotomo Kambe, Riko Takimoto-Ito, Yoko Ueki, Satoshi Nakamizo, Megumu K. Saito, Syuji Takei, and Nobuo Kanazawa. Potential benefits of tnf targeting therapy in blau syndrome, a nod2-associated systemic autoinflammatory granulomatosis. Frontiers in Immunology, May 2022. URL: https://doi.org/10.3389/fimmu.2022.895765, doi:10.3389/fimmu.2022.895765. This article has 27 citations and is from a peer-reviewed journal.

15. (galozzi2024proteomicprofilingof pages 1-2): Paola Galozzi, Sara Bindoli, Chiara Baggio, Ilaria Battisti, Andrea Leonardi, Daniela Basso, Giorgio Arrigoni, and Paolo Sfriso. Proteomic profiling of tears in blau syndrome patients in identification of potential disease biomarkers. International Journal of Molecular Sciences, 25:8387, Aug 2024. URL: https://doi.org/10.3390/ijms25158387, doi:10.3390/ijms25158387. This article has 2 citations.

16. (galozzi2024proteomicprofilingof pages 4-6): Paola Galozzi, Sara Bindoli, Chiara Baggio, Ilaria Battisti, Andrea Leonardi, Daniela Basso, Giorgio Arrigoni, and Paolo Sfriso. Proteomic profiling of tears in blau syndrome patients in identification of potential disease biomarkers. International Journal of Molecular Sciences, 25:8387, Aug 2024. URL: https://doi.org/10.3390/ijms25158387, doi:10.3390/ijms25158387. This article has 2 citations.

17. (brichova2024blausyndromechallenging pages 4-6): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

18. (galozzi2024proteomicprofilingof pages 2-4): Paola Galozzi, Sara Bindoli, Chiara Baggio, Ilaria Battisti, Andrea Leonardi, Daniela Basso, Giorgio Arrigoni, and Paolo Sfriso. Proteomic profiling of tears in blau syndrome patients in identification of potential disease biomarkers. International Journal of Molecular Sciences, 25:8387, Aug 2024. URL: https://doi.org/10.3390/ijms25158387, doi:10.3390/ijms25158387. This article has 2 citations.

19. (NCT06688838 chunk 1): YIKAI YU. Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome. Tongji Hospital. 2017. ClinicalTrials.gov Identifier: NCT06688838

20. (brichova2024blausyndromechallenging media 5971238a): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

21. (brichova2024blausyndromechallenging media 2378c737): Michaela Brichova, Aneta Klimova, Jarmila Heissigerova, Petra Svozilkova, Manuela Vaneckova, Pavla Dolezalova, Dana Nemcova, Marcela Michalickova, Jana Jedlickova, Lubica Dudakova, and Petra Liskova. Blau syndrome: challenging molecular genetic diagnostics of autoinflammatory disease. Genes, 15:799, Jun 2024. URL: https://doi.org/10.3390/genes15060799, doi:10.3390/genes15060799. This article has 4 citations.

22. (galozzi2024proteomicprofilingof pages 12-14): Paola Galozzi, Sara Bindoli, Chiara Baggio, Ilaria Battisti, Andrea Leonardi, Daniela Basso, Giorgio Arrigoni, and Paolo Sfriso. Proteomic profiling of tears in blau syndrome patients in identification of potential disease biomarkers. International Journal of Molecular Sciences, 25:8387, Aug 2024. URL: https://doi.org/10.3390/ijms25158387, doi:10.3390/ijms25158387. This article has 2 citations.